Vaccines Video Recap—November 28, 2025

This biweekly Vaccines video recap highlights late-stage vaccine efficacy, early clinical starts, preventive vaccine trials, and platform-level data across respiratory, infectious, and immune-mediated conditions—plus more developments.

🎯 Watch Our Video Summary Capturing Vaccines News from the Last Two Weeks

Dive deeper

🗓️ Explore weekly details and sources

Week 14 –20 November 2025
Week 21–27 November 2025

📚 See the full Vaccines archive on our research hub page.

Transcript

Welcome to the latest edition of Vaccines Research Updates, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.

In extensive stage small cell lung cancer, a Phase 1b/2 study combining atezolizumab with a dendritic cell vaccine reported median progression free survival of 4.7 months and overall survival of 11.2 months, with 33% of patients alive beyond 24 months. Immune signals were noted in XCR1+ conventional dendritic cells type 1 and in CXCR5+ PD-1+ CD8 T cells. Analyses were presented at SITC 2025, and fuller data will guide clinical impact.

Cancer Research UK has approved funding to launch LungVax, a four year Phase 1 preventive lung cancer vaccine trial in high risk individuals in the United Kingdom, including people post surgery for early stage disease and those identified via NHS targeted checks. The Oxford and UCL led program uses adenoviral technology similar to the Oxford–AstraZeneca Covid vaccine, with dose finding and safety as initial goals.

The UK Horizon trial will evaluate an Epstein–Barr virus vaccine in multiple sclerosis. This Phase 2, sponsored by Moderna and led by the University of Edinburgh, will enroll 180 people recently diagnosed with MS across up to 10 UK sites to assess safety and effects on disease activity. Results could shape clinical and payer discussions depending on design and confounding control.

Pfizer’s mRNA influenza vaccine, in a Phase 3 study of about 18,000 adults during the 2022–2023 season in the United States, South Africa, and the Philippines, showed a 34.5% lower rate of flu like illness versus Fluzone. Coverage against influenza A and B appeared broader, with higher reactogenicity that was mostly mild to moderate.

Indonesia has begun a Phase 1 trial of an inhaled tuberculosis vaccine, enrolling 36 healthy adults aged 18 to 49 in two dose groups, with follow up to day 180. Led by FKUI with Persahabatan Hospital, Etana, and CanSino, this first in human inhaled approach will assess safety and immunogenicity.

Cidara Therapeutics has reached target enrollment of 6,000 participants in the Phase 3 ANCHOR trial of CD388 for prevention of seasonal influenza in high risk populations across the United States and United Kingdom. The randomized, double blind, placebo controlled study tests a single 450 mg subcutaneous dose, with an interim analysis planned in the first quarter of 2026. If successful, this single Phase 3 could support a BLA for a non vaccine influenza preventative.

Blue Lake Biotechnology can resume enrollment in its Phase 1/2a trial of BLB201, an intranasal PIV5 vectored RSV vaccine. After a Type C meeting, the FDA lifted a partial clinical hold, allowing enrollment of RSV negative toddlers from 18 months of age regardless of serostatus criteria used previously. Earlier preliminary signals suggested fewer symptomatic RSV infections versus placebo.

Valneva reported the final Phase 2 readout for its Lyme disease vaccine candidate VLA15. In study VLA15-221, a randomized observer blind trial including pediatric and adult cohorts with yearly boosters at months 18, 30, and 42, strong anamnestic responses were observed across six serotypes six months after the third yearly booster. The data monitoring committee noted no safety concerns.

Stay ahead in Vaccines Research! Like, share, and subscribe for our updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!

Why It Matters

Preventive oncology: LungVax and EBV vaccination test front-end disease interception in high-risk groups.

Respiratory threats: mRNA flu, CD388, intranasal RSV, and inhaled TB broaden tools beyond traditional injected vaccines.

Durability and boosting: VLA15 data support seasonal Lyme strategies pending Phase 3.

Early immuno-oncology signals: Atezolizumab plus DC vaccination shows long-tail survival in a tough SCLC setting.

🗓️ Explore weekly details and sources

Week 14-20 November 2025
Week 21–27 November 2025

📚 See the full Vaccines archive on our research hub page.

FAQ

What did the ES-SCLC atezolizumab + DC vaccine study show?

A Phase 1b/2 reported median OS 11.2 months, PFS 4.7 months, and 33% survival beyond 24 months, with immune correlates in cDC1 and CD8 T cells, in a small cohort [1].

Who will be in the LungVax Phase 1 trial and what is the tech?

High-risk individuals, including those post early-stage lung cancer surgery and people in NHS targeted checks. It uses adenoviral tech similar to Oxford/AZ Covid vaccine [2].

What is the goal of the UK Horizon EBV vaccine trial in MS?

To evaluate safety and whether an EBV vaccine can reduce MS activity in 180 recently diagnosed patients across up to 10 sites [3].

How did Pfizer’s mRNA flu vaccine perform versus Fluzone?

It reduced flu-like illness by 34.5% in a ~18,000-adult Phase 3, with more transient reactogenicity, per NEJM-reported data summarized by NBC [4].

What is Indonesia testing with its inhaled TB vaccine?

A 36-participant Phase 1 assessing safety and immunogenicity of a fine-mist inhaled TB vaccine in adults 18–49, led by FKUI with Etana and CanSino [5].

What does Cidara’s ANCHOR enrollment milestone imply?

The single Phase 3 of CD388 has reached 6,000 participants and could support a BLA in high-risk populations if successful [6].

What changed for Blue Lake’s pediatric RSV program?

FDA lifted a partial clinical hold, allowing enrollment of RSV-negative toddlers from 18 months in the BLB201 Phase 1/2a trial [7].

What do VLA15 Phase 2 results say about boosting?

They show robust anamnestic responses across serotypes six months after a third yearly booster and no new safety issues, supporting seasonal boosting [8].

Entities / Keywords

Atezolizumab; dendritic-cell vaccine; ES-SCLC; cDC1; LungVax; Cancer Research UK; University of Oxford; UCL; EBV vaccine; Horizon trial; Moderna; multiple sclerosis; Pfizer mRNA flu; Fluzone; Indonesia inhaled TB vaccine; FKUI; Etana; CanSino; Cidara Therapeutics; CD388; ANCHOR; Blue Lake Biotechnology; BLB201; PIV5; RSV; Valneva; VLA15; Lyme disease.